• Explore /
  • Poster
  • / A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.

A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.

Abstract Poster

Authors

Adi Diab

Adi Diab

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Adi Diab , Shah Rahimian , Cara L. Haymaker , Chantale Bernatchez , Robert Hans Ingemar Andtbacka , Marihella James , Douglas Buckner Johnson , Joseph Markowitz , Ravi Murthy , Igor Puzanov , Montaser F. Shaheen , Suzanne Swann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02644967

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9515)

DOI

10.1200/JCO.2018.36.15_suppl.9515

Abstract #

9515

Poster Bd #

342

Abstract Disclosures

Similar Posters

Poster

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM).

Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM).

First Author: Marc Isamu Uemura

First Author: Alberto Fusi

First Author: Georgina V. Long

First Author: John Ebben